Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8936614 | 0.84 | MEN1 (0.58) | THRBMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL29882296 | 0.76 | CHRNB4 (0.45) | CHRNB4CHRNA3HSD17B1HSD17B2ALDH1A1 | |
| SCHEMBL5741640 | 0.76 | CHRNB4 (0.45) | CHRNB4CHRNA3HSD17B1HSD17B2ALDH1A1 | |
| SCHEMBL11238612 | 0.65 | PTGS2 (0.50) | THRBKMT2ACHRNB4CHRNA3ALDH1A1 | |
| Bicarbonate SCHEMBL28112645 | 0.65 | HSD17B1 (0.73) | MEN1KMT2AHSD17B1HSD17B2CYP3A4 | |
| SCHEMBL69369 | 0.63 | HSD17B1 (0.88) | MEN1KMT2AHSD17B1HSD17B2ALDH1A1 | |
| SCHEMBL29551999 | 0.63 | HSD17B1 (0.88) | MEN1KMT2AHSD17B1HSD17B2ALDH1A1 | |
| Urea SCHEMBL28406941 | 0.62 | HSD17B1 (0.68) | HSD17B1HSD17B2ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL29356013 | 0.61 | HSD17B1 (0.84) | MEN1KMT2AHSD17B1HSD17B2ALDH1A1 | |
| SCHEMBL51869 | 0.61 | HSD17B1 (0.84) | MEN1KMT2AHSD17B1HSD17B2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242633-A1 | Beta3 adrenergic agonists | EVERS BRITTA (DE) | 2004-12-02 | — | — | US | disclosed |
| US-6730792-B2 | PYRIDINE DERIVATIVES; ANTIDIABETIC, ANTICHOLESTEROL, AND ANTIINFLAMMATORY AGENTS; DECYCLIZATION, DEETHERIFICATION; OBESITY; RAISES HIGH DENSITY LIPOPROTEINS; LOWERS TRIGLYCERIDE LEVELS | ELI LILLY AND COMPANY | 2004-05-04 | — | — | US | disclosed |
| US-20030191156-A1 | Beta3 adrenergic agonists | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2003-10-09 | — | — | US | disclosed |
| EP-1303509-A1 | BETA3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002006276-A1 | BETA3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191156-A1 | Beta3 adrenergic agonists | ADRB3, ADRB1, ADRB2 | THRB 205/4885MEN1 4614/4885KMT2A 3262/4885 |
| US-20040242633-A1 | Beta3 adrenergic agonists | ADRB3, ADRB1, ADRB2 | THRB 217/4885MEN1 4262/4885KMT2A 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.